Navigation Links
General Practitioners Write Most Prescriptions for Mental Health Drugs, According to Study from Thomson Reuters and SAMHSA
Date:9/30/2009

ANN ARBOR, Mich., Sept. 30 /PRNewswire/ -- Fifty-nine percent of all prescriptions filled for psychotropic medications are written by general practitioners, according to a research report published this month in Psychiatric Services.

The study, conducted by researchers from Thomson Reuters and the federal Substance Abuse and Mental Health Services Administration (SAMHSA), analyzed prescribing patterns for psychotropic drugs from August 2006 through July 2007.

Of the 472 million prescriptions written for psychotropic medications during the study period, the researchers found that general practitioners prescribed 62 percent of antidepressants, 52 percent of stimulants (mainly drugs to treat attention deficit hyperactivity disorder), 37 percent of antipsychotics, and 22 percent of anti-mania medications. Pediatricians were included as general practitioners and wrote 25 percent of all stimulant prescriptions.

"The important role of general practitioners in prescribing antidepressant medications and treating depression has been documented," the study authors wrote. "However, the extent to which general practitioners are prescribing other types of psychotropic medications has received less emphasis."

Prescribing of psychotropic medications by non-psychiatrists may improve access to treatment for many patients, the study notes. However, the authors cite concerns about whether patients treated by non-specialists receive psychotherapy, medication monitoring, appropriate intensity of treatment, and treatment consistent with evidence-based guidelines. Moreover, they cite recent evidence(1) that primary care physicians often are unable to find outpatient mental health services for their patients.

Primary care plays a large role in psychotropic drug prescribing and will likely continue to do so. The researchers stress that it is important to ensure the quality of psychiatric treatment in general practice settings across a range of psychiatric conditions.

Study authors were Tami L. Mark, Ph.D., and Katharine R. Levit of Thomson Reuters and Jeffrey A. Buck, Ph.D., from the Center for Mental Health Services at SAMHSA. The study was funded by SAMHSA. The researchers used data from IMS Health, a provider of market intelligence to the pharmaceutical and healthcare industries.

Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto Stock Exchange (TSX: TRI) and New York Stock Exchange (NYSE: TRI). For more information, go to www.thomsonreuters.com.

(1) Cunningham PJ: Beyond parity: primary care physicians' perspectives on access to mental health care. Health Affairs 28:w490-w501,2009

SOURCE Thomson Reuters


'/>"/>
SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
2. Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General
3. APTA Supports Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
4. Surgeon Generals Call to Action to Prevent DVT/PE Praised by NATT as Turning Point
5. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
6. European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting
9. New CoMotion(R) Trials Software by General Dynamics Enables Rapid, Interactive Sharing of Real-time Data for Clinical Trials
10. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
11. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ReportsnReports.com adds "Pulmonary Arterial ... report that provides an overview of the PAH ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Pulmonary Arterial ...
(Date:4/29/2016)... 29, 2016 ... Sanofi, leader mondial et ... résultats pour le premier trimestre 2016. ... Contamine, commente les résultats du premier ... pour le reste de l,année. ...
(Date:4/29/2016)... April 29, 2016 Automation is ... laboratory due to the growing demands for productivity in ... contemporary automated systems are already adept of a wide ... tedious and manual labor. Instrumentation continues to evolve, and ... conceivable just a few years ago. Originally used mostly ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, RN, ... the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coalition ... muscular dystrophy, and funding for Duchenne research, participated in the April 25 U.S. ... Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott Conference Center in ...
(Date:4/29/2016)... ... 29, 2016 , ... The Society for Assisted Reproductive Technology ... required to report in vitro fertilization (IVF) delivery rates to both ... of assisted reproductive technologies in the United States. , This year, SART’s ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... The ... the workforce is aging – meaning that there is an urgent need for highly ... and interactive training solution, delivering a multi-pronged approach to train and retain care managers, ...
Breaking Medicine News(10 mins):